Jim Kramer here to share with you a sample of my take on the market from today's

CNBC Investing Club morning meeting.

This morning, when we got a 9-1-1 down, the late Mark Haynes, and I don't know how many

of you were able to watch Mark, but Mark, particularly at the beginning of when I moved over,

did a huge amount of charting, a huge

amount of work on individual stocks. At that point, he was allowed to own individual stocks and

really did encourage him. And he always said to me, Jim, if there's one thing that is certain,

at 9 to 1, you'll buy. And he always put it the same way. You find something. And I think

that we have been true to Mark's words this morning. And I think that we have been true to Mark's

words this morning. Yeah, I think we've been true to his words for many, many years. But yeah,

this morning we added to Abbott Labs, which is obviously, like, health care very out of favor.

Abbott Labs out of favor company specific issue. They do Yes, because of a tangential tie-up with J&J, J&J has a massive number of lawsuits.

This has a very small number.

And I think that all drug firms at one time or another are faced with what Abbott is, but

where J&J is very special.

Right, that's J&J is TALC. Abbott is Baby but J&J is very special. Right. That's J&J is talc.

Abbott is baby formula, which is a medical need.

It's a prescription, but this is a failure to warn situation, resulting back to a loss by

wreck at Ben Keiser.

Which is not as good a company, for sure.

But, no, not at all.

But Abbott, I mean, one of the fastest growing companies in

...